The current progress in biomedical science works on the basis of the identification of a gene, a protein, a biochemical function and a biological activity followed by a possible drug identification processing. This information seems to be in a linear cascade. Many Biotechs have invested on this linear cascade billions of dollars. 

A typical example of a protein is the CREB-binding protein CREBBP or CBP, which is a Histone Acetyltransferase and might be used as a “scaffold” in protein complexes. Is the biological property of CBP a copy-paste expression of its enzymatic activity? Does the presence of CBP in a complex a reflection of CBP enzymatic activity or the presence of a protein in a complex remodifies its biological activities?

In fact do we search an obstacle in many drug screening assays when testing enzymatic activities that are far representative of the real biological property of the target protein in a specific biological/topological environment?

More Vassilis Doucas's questions See All
Similar questions and discussions